Candriam Luxembourg S.C.A. Has $9.15 Million Stake in NeoGenomics, Inc. (NASDAQ:NEO)

Candriam Luxembourg S.C.A. raised its position in NeoGenomics, Inc. (NASDAQ:NEOGet Rating) by 3.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 268,194 shares of the medical research company’s stock after acquiring an additional 8,074 shares during the quarter. Candriam Luxembourg S.C.A. owned approximately 0.22% of NeoGenomics worth $9,151,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Wellington Management Group LLP lifted its position in shares of NeoGenomics by 36.7% in the third quarter. Wellington Management Group LLP now owns 7,585,848 shares of the medical research company’s stock valued at $365,942,000 after buying an additional 2,037,787 shares during the last quarter. Artisan Partners Limited Partnership lifted its holdings in NeoGenomics by 43.1% during the 3rd quarter. Artisan Partners Limited Partnership now owns 6,931,041 shares of the medical research company’s stock valued at $334,353,000 after purchasing an additional 2,086,662 shares during the last quarter. Brown Advisory Inc. boosted its position in NeoGenomics by 10.9% during the fourth quarter. Brown Advisory Inc. now owns 3,716,012 shares of the medical research company’s stock worth $126,791,000 after purchasing an additional 366,464 shares during the period. Macquarie Group Ltd. increased its holdings in shares of NeoGenomics by 134.3% in the third quarter. Macquarie Group Ltd. now owns 2,042,456 shares of the medical research company’s stock valued at $98,528,000 after purchasing an additional 1,170,745 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of NeoGenomics by 1.2% in the third quarter. Geode Capital Management LLC now owns 2,038,725 shares of the medical research company’s stock valued at $98,348,000 after purchasing an additional 23,421 shares during the period. 95.03% of the stock is owned by institutional investors.

Shares of NeoGenomics stock opened at $8.39 on Thursday. The company has a current ratio of 7.93, a quick ratio of 7.64 and a debt-to-equity ratio of 0.50. The company has a market cap of $1.05 billion, a PE ratio of -26.22 and a beta of 0.86. The company has a 50 day moving average of $12.45 and a 200-day moving average of $23.51. NeoGenomics, Inc. has a 1-year low of $7.26 and a 1-year high of $54.74.

NeoGenomics (NASDAQ:NEOGet Rating) last released its earnings results on Wednesday, April 27th. The medical research company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.04. NeoGenomics had a negative return on equity of 6.62% and a negative net margin of 7.33%. The firm had revenue of $117.17 million during the quarter, compared to analysts’ expectations of $116.44 million. During the same period in the prior year, the company earned ($0.06) earnings per share. The company’s quarterly revenue was up 1.4% on a year-over-year basis. Research analysts forecast that NeoGenomics, Inc. will post -0.98 earnings per share for the current year.

In other news, CFO William Bonello sold 3,209 shares of the firm’s stock in a transaction that occurred on Monday, March 7th. The shares were sold at an average price of $18.29, for a total value of $58,692.61. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 1.00% of the company’s stock.

A number of brokerages recently commented on NEO. Zacks Investment Research lowered shares of NeoGenomics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 4th. SVB Leerink lowered their target price on NeoGenomics from $45.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 29th. StockNews.com raised NeoGenomics to a “sell” rating in a report on Thursday, May 12th. Bank of America downgraded NeoGenomics from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $25.00 to $18.00 in a report on Tuesday, March 29th. Finally, Craig Hallum reduced their target price on shares of NeoGenomics from $46.00 to $30.00 in a research report on Thursday, February 24th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $24.64.

NeoGenomics Company Profile (Get Rating)

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers.

Further Reading

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.